HIV-1 virus

Down, but hardly out, at comeback-primed Chembio

By GREGORY ZELLER // Operating and net losses that more than tripled year-over-year tell only part of the story of Chembio Diagnostic Systems Inc.’s first quarter. That was the message Tuesday from John Sperzel III, chief executive of the point-of-care diagnostics specialist, who addressed investors in a conference call after the firm shared the results of the first quarter of its fiscal 2017, which ended March 31. It was another down quarter for the Medford-based…


Before the cure, an HIV inhibitor?

By GREGORY ZELLER A cure for AIDS? Let’s not get ahead of ourselves. Few people understand the molecular world like Stony Brook prof Carol Carter, and the longtime researcher will tell you that such a grandiose achievement may be a decade away or more. And besides, she’s not working on a cure. But her unique method of targeting cellular factors that release the HIV-1 virus from infected cells – rather than targeting the virus itself –…